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Whilemitochondrial dysfunction is emerging as key in
Parkinson’s disease (PD), a central question remains
whether mitochondria are actual disease drivers and
whether boostingmitochondrial biogenesis and func-
tion ameliorates pathology. We address these ques-
tions using patient-derived induced pluripotent
stem cells and Drosophila models of GBA-related
PD (GBA-PD), the most common PD genetic risk. Pa-
tient neuronsdisplay stress responses,mitochondrial
demise, and changes in NAD+ metabolism. NAD+
precursors have been proposed to ameliorate age-
related metabolic decline and disease. We report
that increasing NAD+ via the NAD+ precursor nicotin-
amide riboside (NR) significantly ameliorates mito-
chondrial function in patient neurons. Human
neurons require nicotinamide phosphoribosyltrans-
ferase (NAMPT) to maintain the NAD+ pool and utilize
NRK1 to synthesize NAD+ from NAD+ precursors.
Remarkably, NR prevents the age-related dopami-
nergic neuronal loss and motor decline in fly models
of GBA-PD. Our findings suggest NR as a viable clin-
ical avenue for neuroprotection in PD and other
neurodegenerative diseases.INTRODUCTION
Mitochondrial dysfunction has been proposed as a key mecha-
nism in many neurodegenerative diseases. Among others, Par-2976 Cell Reports 23, 2976–2988, June 5, 2018 ª 2018 The Authors.
This is an open access article under the CC BY license (http://creativekinson’s disease (PD) stands out due to the role of PD-linked
genes in mitochondrial function and dynamics (Exner et al.,
2012). Evidence for mitochondrial dysfunction in PD was first
described in the 1980s by Schapira et al., who showed
complex I (CI) defects in cells and tissues from PD patients
(Schapira et al., 1989). Substantial progress has been made
since, and genetic and biochemical studies now indicate that
mitochondrial dysfunction and cellular energy failure are key to
PD (Jansen et al., 2017). In this respect, recent studies have
shown that the activation of pathways related to mitochondrial
biogenesis and energy metabolism, such as the NAD+/sirtuin 1
(SIRT1) pathway, provides protection against aging-related dis-
ease (Rajman et al., 2018). Similar approaches could be easily
translated into treatment for PD. However, it is still unclear
whether mitochondrial defects are actual disease drivers and
increasing mitochondrial biogenesis provides neuroprotection
in PD. In addition, little is known about NAD+ metabolism and
availability of NAD+ precursors in human neurons. Here, we
have addressed these fundamental questions in an induced
pluripotent stem cell (iPSC) neuronal model of PD bearing muta-
tions in the lysosomal enzyme b-Glucocerebrosidase (GBA)
gene (GBA-PD), themost common genetic risk for PD (Sidransky
et al., 2009). b-Glucocerebrosidase (GCase) activity is reduced
not only in mutation carriers but also in idiopathic PD and healthy
individuals at older age (Gegg et al., 2012; Rocha et al., 2015),
pointing toward a general role for GCase in brain aging and
neurodegenerative processes. Importantly, patients with GBA
mutations represent an etiologically homogeneous subgroup of
PD, therefore providing the ideal cohort for precision medicine
approaches.
The pathogenetic mechanisms involved in GBA-PD are
only partially understood and include autophagic defects,
increased a-synuclein aggregation, calcium dyshomeostasis,commons.org/licenses/by/4.0/).
(legend on next page)
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and endoplasmic reticulum (ER) stress (Migdalska-Richards and
Schapira, 2016). GCase is a lysosomal enzyme that catalyzes the
hydrolysis of glucosylceramide (GlcCer), a membrane glyco-
sphingolipid, to ceramide and glucose, and both loss and gain
of its enzymatic function may contribute to disease. According
to the loss-of-function hypothesis, GCase deficiency causes
substrate accumulation that alters lysosomal function and pro-
motes a-synuclein aggregation (Jo et al., 2000; Velayati et al.,
2010; Mazzulli et al., 2011). GCase is glycosylated and folded
in the ER and subsequently trafficked through the Golgi to the
lysosome. According to the gain-of-function hypothesis, GBA
mutations interfere with the folding process in the ER, leading
to ER-associated degradation, ER stress, and activation of the
unfolded protein response (UPR) (Maor et al., 2013; Fernandes
et al., 2016). Interestingly, mitochondrial dysfunction has been
described in experimental models of GCase deficiency (Osel-
lame et al., 2013; Keatinge et al., 2015; Cleeter et al., 2013). How-
ever, whether mitochondrial function is altered in PD patients
with GBA mutations (GBA-PD) and the mechanisms underlying
such demise are still unknown. Furthermore, whether improving
mitochondrial biogenesis and function represents an effective
therapeutic strategy for PD needs to be investigated.
RESULTS
iPSC-Derived Neurons from GBA-PD Patients Show
Defects in Mitochondrial Function
To investigate whetherGBA is linked to mitochondrial function in
human neurons, iPSC lines from PD patients with heterozygous
GBA mutations (N370S, L444P, and RecNcil), as well as corre-
sponding isogenic gene-corrected (GC) and unaffected controls
(Scho¨ndorf et al., 2014) (Table S1), were differentiated into dopa-
minergic (DA) neurons, and mitochondrial morphology was
examined by transmission electron microscopy (TEM). Morpho-
metric analysis revealed altered cristae morphology in GBA-PD
neurons compared to isogenic GC and healthy controls (Figures
1A, 1B, and S1A). In addition,GBA-PD neurons showed a signif-
icant increase in mitochondrial diameter (Figure 1C). Next, we
measured oxygen consumption rates (OCRs) and found that
GBA-PD neurons displayed significantly reduced basal respira-Figure 1. Mitochondrial Function in GBA-PD iPSC Neurons
(A–C) Mitochondrial morphology in isogenic gene-corrected (GC) controls and G
(A) Representative TEM images of mitochondria are shown (L444P GBA-PD and
(B) Quantification of mitochondrial cristae morphology in isogenic GC and GBA-P
(C) Mitochondrial major diameter. Data are presented as mean ± SD (n = 299 G
analyzed; two-tailed t test).
(D) Oxygen consumption rate (OCR) trace for isogenic GC and GBA-PD (N370S
sented as mean ± SD (n = 8; two-tailed t test).
(E) Quantification of basal, maximal, ATP-linked respiration, and spare respiratory
SD (n = 8; two-tailed t test).
(F) Complex I (CI) activity in enrichedmitochondria from isogenicGBA-PD (N370S
tailed t test).
(G) Mitochondrial ROS (mtROS) levels in GBA-PD (N370S, L444P, RecNcil) and G
(n = 5; two-tailed t test).
(H) Mitochondrial membrane potential in isogenic GC andGBA-PD (N370S, L444P
SEM (n = 5; two-tailed t test).
(I) Citrate synthase (CS) activities in GC and GBA-PD (N370S, L444P, RecNcil) iP
(J) Mitochondrial sphingolipid profile of isogenic GC andGBA-PD (N370S, L444P
as mean + SEM (n = 7 independent mitochondrial purifications; two-tailed t test)
2978 Cell Reports 23, 2976–2988, June 5, 2018tion and decreased maximal OCR as well as ATP-linked OCR
and spare respiratory capacity (SRC) compared to isogenic con-
trols (Figures 1D and 1E). Similarly, basal respiration, maximal
OCR, and ATP-linked OCR and SRC were significantly reduced
in GBA-PD neurons compared to unrelated unaffected controls
(Figure S1B). Western blot analysis revealed an increase in the
level of respiratory chain complex subunits in GBA-PD neurons
compared to isogenic controls, but this increase did not
reach statistical significance (Figures S1C and S1D). We next
measured CI activity in enriched mitochondrial fractions from
GBA-PD iPSC neurons and GC controls. CI activity was signifi-
cantly reduced in GBA-PD neurons compared to isogenic
controls (Figure 1F). Consistent with these findings, GBA-PD
neurons produced significantly higher amounts of mitochondrial
reactive oxygen species (mtROS) than isogenic controls (Fig-
ure 1G). However, mitochondrial membrane potential and mito-
chondrial mass were not significantly changed in GBA-PD
neurons (Figures 1H and 1I). Of note, no significant difference
in the degree of mitochondrial function was observed among
different GBA genotypes, suggesting that the genotypes exam-
ined in this study (RecNcil, L444P, and N370S) equally affect
mitochondria (Figures S1E–S1I). To get further insight into the
mechanisms underlying mitochondrial dysfunction in GBA-PD,
we examined the GCase substrate sphingolipid composition of
mitochondria from GBA-PD neurons and isogenic controls by
high-performance liquid chromatography tandem mass spec-
trometry (HPLC-MS/MS). To this end, mitochondria were iso-
lated from iPSC neurons with a high degree of purity. Western
blot analysis showed high level of enrichment of isolated mito-
chondria with a small amount of non-mitochondrial organelle
contamination (Figure S1J). Quantification of individual species
of GlcCer revealed the absence of GlcCer accumulation in pa-
tient mitochondria with only a significant increase of C16-GlcCer
(Figure 1J).
iPSC-Derived Neurons from GBA-PD Patients Show
Defects in Mitochondrial Dynamics
Next, we examined the level of mitochondrial fission (DRP1 and
Fis1) and fusion (OPA1 andMfn1) proteins inGBA-PD iPSC neu-
rons and isogenic controls. Immunoblot analysis revealed aBA-PD iPSC neurons.
GC controls) (scale bar, 500 nm).
D (N370S, L444P) iPSC-derived neurons (n = 3; two-sided Fisher’s exact test).
C and n = 264 GBA-PD mitochondria from 3 independent experiments were
, L444P, RecNcil) iPSC neurons. Data are normalized to cell number and pre-
capacity (SRC). Data are normalized to cell number and presented as mean +
, L444P) and GC iPSC neurons. Data are expressed asmean + SEM (n = 5; two-
C iPSC neurons. Data are normalized to GC and represented as mean + SEM
, RecNcil) iPSC neurons. Data are normalized to GC and presented as mean +
SC neurons. Data are presented as mean + SEM (n = 5; two-tailed t test).
) iPSC neurons. Data are normalized to inorganic phosphate (Pi) and presented
.
Figure 2. Mitochondrial Dynamics in GBA-PD iPSC Neurons
(A and B) Western blot of DRP1, Mfn1, and Fis1 in isogenic GBA-PD (N370S, L444P) and gene-corrected (GC) iPSC neurons (A). Vinculin was used as a loading
control. Quantification of western blots is shown in (B). Data are normalized to GC and presented as mean + SEM (n = 5).
(C and D) Western blot analysis of OPA-1 processing (C). The L-OPA1/S-OPA-1 ratio is shown in (D). Data are presented as mean + SEM (n = 5; two-tailed t test).
(legend continued on next page)
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reduction in DRP1, OPA1, and Mfn1 levels in GBA-PD neurons
(Figures 2A–2D). On the other hand, there was an increase of
Fis1 in GBA-PD neurons (Figures 2A and 2B). However, these
differences did not reach statistical significance. Interestingly,
the ratio between the long and short form of OPA1 was signifi-
cantly increased inGBA-PD neurons compared to isogenic con-
trols, suggesting an impairment of mitophagy (MacVicar and
Lane, 2014) (Figures 2C and 2D). GBA-PD neurons showed a
significant reduction of mitochondrial-lysosomal co-localization
compared to GC controls, as assessed by confocal microscopy
and Amnis ImageStream flow cytometry (Figures 2E, 2F, S2A,
and S2B). In line with these findings, the expression of the mi-
tophagy adaptor protein BNIP3L/NIX was significantly reduced
in GBA-PD compared to isogenic controls (Figure 2G).
Mitochondrial Function Is Altered in GBA Knockout
iPSC-Derived Neurons
To assess the impact of loss of GCase enzymatic function on
mitochondria in the absence of gain-of-function mechanisms,
we generated GBA knockout (KO) iPSCs using clustered regu-
larly interspaced short palindromic repeats (CRISPR)-Cas9 (Fig-
ures S3A–S3F). GBA was knocked out in two healthy control
iPSC lines and one GBA-PD N370S iPSC line (Table S2). All
GBA KO clones showed complete loss of GCase protein and
its enzymatic activity (Figures S3E and S3F). No significant differ-
ence in DA neuronal differentiation potential was observed
among GBA KO iPSCs and corresponding parental lines as as-
sessed by quantification of bIII-tubulin- and tyrosine hydroxylase
(TH)-positive neurons (>80% neurons, of which on average 40%
of cells in both controls and GBA KO lines expressed TH). GBA
KO iPSC-derived neurons exhibited accumulation of the GCase
substrates GlcCer and glucosylsphingosine as revealed by
HPLC-MS/MS (Figures S3G). A significant increase of C16-gal-
actosylceramide was also observed (Figure S3I). No significant
change in levels of other sphingolipids was detected (Figures
S3H and S3I). Two GBA KO clones were selected from each
parental iPSC line and used for further experiments (Table S2).
As observed in GBA-PD neurons, morphometric analysis re-
vealed ultrastructural abnormalities in GBA KO iPSC-neurons
compared to isogenic controls (Figures 3A and 3B). Similar to
what we observed in GBA-PD neurons, GBA KO neurons
showed significantly reduced basal and maximal respiration as
well as ATP-linked OCR and SRC (Figure 3C). Despite the
consistent trend for decreased CI activity in GBA KO neurons,
the values did not reach statistical significance (Figure 3D).
GBA KO neurons showed elevated levels of mtROS
(Figure 3E). Furthermore, we did not observe significant
changes of mitochondrial membrane potential (Figure 3F).
HPLC-MS/MS analysis of mitochondria purified from GBA KO
iPSC-derived neurons showed a significant accumulation of all
subtypes of the GCase substrates GlcCer and glucosylsphingo-
sine (Figure 3G).(E) Immunostaining of differentiated iPSC cultures for MAP2 (magenta), TOM20 (
Scale bar, 20 mm.
(F) Colocalization between LAMP1 and TOM20. Data are presented as mean + S
(G) BNIP3L mRNA levels in isogenic GC andGBA-PD (N370S, L444P) iPSC-deriv
as mean + SEM (n = 5; two-tailed t test).
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Interestingly, when comparing OCRs and CI activity in the
isogenic lines (GBA-PD N370S, GC control and GBA KO), no
gene dosage effect was found (Figures S3J and S3K). These
data suggest that different mechanisms contribute to mitochon-
drial defects in heterozygous GBA-PD patient and GBA KO neu-
rons. One of such mechanisms could be the UPR and ER stress
that have been previously observed inGBA-PD (Fernandes et al.,
2016). To dissect the contribution of gain- and loss-of-function of
mutant GCase, we measured the levels of the ER chaperone
immunoglobulin-binding protein (BiP) by western blot in GBA-
PD N370S iPSC-derived neurons as well as isogenic controls
and isogenic GBA KO neurons. Levels of BiP were increased in
GBA-PD neurons compared to isogenic controls and isogenic
GBA KO neurons (Figure 4A). Consistent with these findings,
RNA levels of spliced X-box-binding protein-1 (XBP1s) were
significantly increased in GBA-PD, but not in isogenic GBA KO
neurons, suggesting activation of the IRE1 related branch of
ER stress (Figure 4B). Healthy control-derived GBA KO neurons
showed levels of BiP similar to their isogenic controls (Fig-
ure S3L). In addition, levels of phospho-eIF2a were significantly
increased in GBA-PD, but not in isogenic GBA KO neurons, as
compared to GC controls (Figure 4C). Consistent with these find-
ings, levels of phospho-PERK were increased only in GBA-PD
neurons as compared to GC controls (Figure 4D).
NAD+ Metabolism Is Altered in GBA-PD iPSC-Derived
Neurons
Mitochondrial dysfunction and increased oxidative stress are
hallmarks of aging and have been linked to the decline of intra-
cellular levels of NAD+ (Mouchiroud et al., 2013). To examine
whether GBA mutations lead to changes in NAD+ metabolism,
we measured the expression of the NAD+ biosynthetic enzymes
nicotinamide mononucleotide adenylyltransferases (NMNATs).
mRNA levels of NMNAT2 were significantly decreased in GBA-
PD neurons compared to isogenic controls, whereas levels of
NMNAT1 and NMNAT3 were unchanged (Figure 5A). NMNAT2
levels were unchanged in GBA KO neurons (Figure S3M). Levels
of nicotinamide phosphoribosyltransferase (NAMPT), the rate-
limiting enzyme in the NAD+ salvage synthesis pathway, were
similar in both groups (GBA-PD and GC controls), as assessed
by qRT-PCR (Figure 5A). Next, we measured the adenine and
pyridine nucleotide pool in GBA-PD and isogenic control as
well as GBA KO iPSC-neurons by targeted metabolomics using
liquid chromatography-mass spectrometry (LC-MS). The intra-
cellular NAD+ content was maintained in GBA-PD and GBA
KO neurons (Figure S4). To exclude that the observed absence
of significant changes of NAD+ levels could be linked to the
absence of overt neurodegeneration in our stem cell-based
model system, we also examined the NAD+metabolome in adult
gba+/+, gba/, and gba+/ whole zebrafish brains. Adult gba/red), and LAMP1 (green). Cell nuclei were counterstained with Hoechst (blue).
EM (n = 5; two-tailed t test).
ed neurons. Data are normalized on Rplp0 and OAZ1 and to GC and presented
Figure 3. Mitochondrial Function in Human
GBA KO iPSC Neurons
(A and B) Mitochondrial morphology in isogenic
healthy control (CTRL) andGBAKO iPSC neurons.
Representative TEM images of mitochondria (A;
scale bar, 500 nm). Quantification of mitochondrial
cristae morphology in isogenic CTRL andGBA KO
iPSC-neurons (B). Data are presented as mean +
SEM (n = 3; two-sided Fisher’s exact test).
(C) Mitochondrial respiration. Data are presented
as mean + SD (n = 5–7; two-tailed t test).
(D) CI activity in isogenic CTRL and GBA KO iPSC
neurons. Data are expressed as mean + SEM
(n = 5; two-tailed t test).
(E) mtROS levels normalized to CTRL and pre-
sented as mean + SEM (n = 5; two-tailed t test).
(F) Mitochondrial membrane potential. Data are
presented asmean + SEM (n = 5; two-tailed t test).
(G) Mitochondrial sphingolipid profile of CTRL and
GBA KO iPSC-neurons. GlcCer and glucosyl-
sphingosine levels normalized by inorganic
phosphate (Pi). Glucosylsphingosine was below
detection limit in control mitochondria. Data are
presented as mean + SEM (n = 4 independent
mitochondrial purifications; two-tailed t test).zebrafish recapitulate the key pathological aspects of PD,
including DA neuronal loss, early microglial activation, and mito-
chondrial dysfunction (Keatinge et al., 2015). Metabolomic ana-
lyses revealed that the NAD+ pool was maintained in brains of
adult gba+/ and gba/ zebrafish (Figure S5). However, a signif-
icant increase in nicotinamide mononucleotide (NMN) was
observed in gba/ compared to gba+/+ zebrafish brains as
well as in gba/ compared to gba+/- brains (Figure S5), suggest-
ing an alteration of NAD+ metabolism. To rule out the possibility
that the heterogeneity of the cell culture and whole brain tissues
influences the results, we then employed the biosensor Peredox
tomonitor the cytosolic NADH/NAD+ ratio in single iPSC-derived
neurons with live-cell imaging (Hung et al., 2011). The NAD+/
NADH redox state was significantly reduced in GBA-PD iPSCCell Rneurons, suggesting reduced level of
available NAD+ (Figure 5B). No significant
change was observed in GBA KO neu-
rons (Figure S3N).
The NAD+ Precursor Nicotinamide
Riboside Rescues Mitochondrial
Defects in GBA-PD iPSC-Derived
Neurons
Next, we tested the ability of different
NAD+ precursors to increase NAD+
levels in human iPSC-derived neurons.
Control iPSC-derived neurons were
treated with nicotinamide (NAM), NMN,
or nicotinamide riboside (NR), and NAD+
levels were measured using a NAD+
cycling assay. NR and NMN showed the
strongest effect in boosting NAD+ levels
(Figure S6A). As NR represents a prom-ising approach, as shown by pharmacokinetic studies in healthy
subjects (Trammell et al., 2016), we investigated the ability of NR
to rescue GBA-linked mitochondrial defects. NR significantly
increased NAD+ and NADH levels in GBA-PD neurons (Figures
S6B and S6C). NR treatment resulted in an increase in expres-
sion of markers of mitochondrial biogenesis (TFAM) and mito-
chondrial UPR (mtUPR) (HSP60) (Figure 5C). Consistent with
these findings, mitochondrial DNA content and mitochondrial
mass were increased after 48 hr in NR-treated samples (Figures
5D and 5E). The effect of NR was abrogated by EX527, a SIRT1-
specific inhibitor, suggesting that SIRT1 is one of the mediators
of NR function (Figure S6D). Importantly, NR restored mitochon-
drial cristae morphology and significantly reduced mtROS pro-
duction in GBA-PD neurons (Figures 5F–5H). In parallel, NReports 23, 2976–2988, June 5, 2018 2981
Figure 4. ER Stress Responses in GBA-PD
and GBA KO iPSC Neurons
Analysis of ER stress responses and UPR was
performed in isogenic GBA-PD (N370S), gene-
corrected (GC) controls, and isogenic GBA KO
(clones 4 and 16) iPSC neurons.
(A) Representative western blots showing BiP
levels in isogenic GBA-PD, GC, and GBA KO iPSC
neurons. BiP intensity bands were normalized to
GAPDH and the corresponding isogenic control.
Data are expressed as mean + SEM (n = 5; one-
way ANOVA).
(B) Analysis of XBP1 splicing (XBP1s). mRNA levels
of XBP1s were measured by qPCR. Representa-
tive agarose gel electrophoresis of qRT-PCR
products is shown. For quantification, GAPDH
served as reference gene. Data are expressed as
mean + SEM (n = 5; one-way ANOVA).
(C) Representative western blots showing phos-
pho-eIF2a/eIF2a levels in isogenic GBA-PD, GC,
and GBA KO iPSC-derived neurons. For quantifi-
cation, phospho-eIF2a intensity bands were
normalized to total eif2a and the corresponding
isogenic control. Data are expressed as mean +
SEM (one-way ANOVA). Gel loading as in (A).
(D) Representative western blots showing phos-
pho-PERK/PERK levels in isogenic GBA-PD, GC,
and GBA KO iPSC-derived neurons. Data are ex-
pressed as mean + SEM (n = 5; one-way ANOVA).treatment significantly reduced themitochondrial membrane po-
tential (Figure 5I). Similar results were observed when GBA KO
neurons were treated with NR (Figures S6E–S6G). With regard
to the observed defects in mitochondrial dynamics, NR altered
the levels of mitochondrial shaping proteins, with a nonsignifi-
cant increase in DRP1, Mfn1, and OPA1 and a slight decrease
in Fis1 (Figures 5J and 5K). The decreased levels of mitochon-
drial DNA content observed at 24 hr after NR treatment would
suggest an increased mitochondrial clearance (Figure 5D). In
line with these findings, NR was able to increase the levels of
BNIP3L/NIX inGBA-PD neurons (Figure 5L). NR did not enhance
mitochondrial respiration (Figures S6H and S6I). On the contrary,
a significant decrease in basal respiration was observed inGBA-
PD iPSC-derived neurons treated with NR (Figure S6H). In addi-
tion, NR treatment did not alter protein levels of BiP in GBA-PD
neurons (Figure S6J). To confirm that increased NAD+ levels
are responsible for the phenotypic rescue, we treated cells
with the poly(ADP-ribose)-polymerase (PARP) inhibitor PJ34
that, differently from NAD+ precursors, increases NAD+ levels
by inhibiting its consumption. Similar to NR, PJ34 significantly
increased NAD+ levels in human-iPSC-derived neurons and
rescued mitochondrial defects in GBA-PD neurons (Figures
S7A–S7E). Taken together, these results suggest that increasing
NAD+ levels rescues mitochondrial dysfunction via increased
levels of NAD+ in patient-derivedGBA-PD andGBAKOneurons.
Increasing NAD+ Improves Autophagy in GBA-PD and
GBA KO Neurons
GBA mutations affect autophagy and lysosomal function, lead-
ing to autophagic block, defects in autophagosome clearance,
and altered lysosomal recycling (Scho¨ndorf et al., 2014; Magal-2982 Cell Reports 23, 2976–2988, June 5, 2018haes et al., 2016). To examine the effects of NR on autophagy,
we treatedGBA-PD andGBAKO neurons with NR and assessed
parameters of autophagic function. NR treatment did not alter
the levels of LC3II at basal conditions; however, it significantly
increased LC3II levels in patient neurons treated with leupeptin
and ammonium chloride, suggesting an increase of synthesis
and clearance of autophagosomes (Figures S7F–S7I). The auto-
phagic flux was significantly increased in GBA KO neurons and
showed a nonsignificant increase in GBA-PD neurons after NR
treatment (Figures S7F–S7I).
NR Metabolism and NAD+ Availability in Human iPSC-
Derived Neurons
To examine pathways of NAD+ maintenance and NAD+ precur-
sors utilization, control iPSC-derived neurons were treated with
the NAMPT inhibitor FK866, and NAD+ levels were measured.
FK866 treatment decreased intracellular NAD+ levels by more
than 90% (Figure 6A). However, FK866 treatment did not alter
the sensitivity of human neurons to NR treatment (Figure 6A),
indicating that NR is metabolized into NAD+ in a NAMPT-inde-
pendent pathway. We next measured the expression levels of
the NAD+ biosynthesis enzymes NR kinase 1 and 2 (NRK1 and
NRK2) (Bieganowski and Brenner, 2004). In undifferentiated
iPSCs, NRK2 showed higher expression levels; on the contrary,
levels of NRK1 were significantly higher in iPSC-derived neurons
(Figure 6B). The role of NRKs in NAD+ metabolism in human
neurons is still unknown. Given its high expression, we aimed
to investigate whether NRK1 is essential for NR metabolism
into NAD+ in human neurons. Of note, mRNA levels of NRK1
were not affected by NR treatment (Figure 6C). Next, we
knocked down NRK1 in control iPSC-derived neurons using
AD
B
E
F G
C
H
I J K L
Figure 5. Nicotinamide Riboside Reverts Mitochondrial Defects in GBA-PD iPSC Neurons
(A) NMNAT1, NMNAT2, NMNAT3, and NAMPT mRNA levels in isogenic GC andGBA-PD (N370S, L444P) iPSC neurons. Data were normalized to the level of the
housekeeping genes Rplp0 and OAZ and expressed as fold change over PD. Data are expressed as mean + SEM (n = 5; two-tailed t test).
(B) The NAD+/NADH redox state was measured in iPSC-derived neurons using the biosensor Peredox. Results are presented as mean + SEM (n = 5; two-tailed t
test).
(legend continued on next page)
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Figure 6. NR Metabolism and Availability in
Human iPSC Neurons
(A) Control iPSC neurons were treated with NR
with or without the NAMPT inhibitor FK866, and
NAD+ levels were measured using a NAD+ cycling
assay. Data are expressed as fold changes over
untreated neurons and presented as mean + SEM
(n = 3; one-way ANOVA). #, significance compared
with FK866-treated neurons.
(B) NRK1 and NRK2 mRNA levels were measured
in control undifferentiated human iPSCs and iPSC-
derived neurons. Data are normalized to Rplp0
levels and expressed as mean + SEM (n = 3; two-
tailed t test).
(C) NRK1 mRNA levels were measured in control
iPSC neurons with or without NR treatment. Data
are normalized to control and presented as
mean + SEM (n = 3).
(D) Knockdown efficiency of NRK1 in iPSC neu-
rons was determined by qRT-PCR and normalized
to non-targeting shRNA. Data are presented as
mean + SEM (n = 3; two-tailed t test).
(E) Representative western blot for NRK1 showing
knockdown efficiency in iPSC neurons.
(F) Scramble (Scrb) or NRK1 knockdown control
iPSC neurons were treated with NR, and NAD+
levels weremeasured using aNAD+ cycling assay.
Data are expressed as fold changes over un-
treated and presented as mean + SEM (n = 3; one-
way ANOVA).
(G) Control and GBA-PD (N370S) iPSC neurons
were treated with 0.5mMNR for 24 hr and LC-MS-
based targeted NAD+ metabolomics was per-
formed. Levels of NAD, NAM, and NMN are
shown. Data are normalized on protein concen-
tration and presented as mean ± SD (n = 7 inde-
pendent differentiations; two-tailed t test).lentiviral-mediated short hairpin RNA (shRNA) (Figures 6D and
6E). NRK1 knockdown did not affect basal levels of NAD+ in neu-
rons, as assessed by a NAD+ cycling assay, whereas NR treat-
ment was unable to significantly increase NAD+ levels in NRK1
knockdown neurons (Figure 6F). These data suggest that
NRK1 is essential for exogenous NR metabolism in human neu-(C) iPSC-derived neurons with GBA mutations (N370S and L444P) were treated w
markers were measured by qRT-PCR. Data are normalized to untreated and exp
(D) qRT-PCR was performed to determine mtDNA content as mitochondrial (16S
24- or 48-hr treatment with NR. Data are normalized to untreated and expressed
(E) Western blot showing TOM70 levels. Protein levels are normalized to GAPDH
(n = 3; two-tailed t test).
(F and G) Mitochondrial morphology was assessed by TEM. Representative TEM
treated with NR (F; scale bar 500 nm). Quantification of mitochondrial cristaemorp
Fisher’s exact test).
(H) mtROS in GBA-PD (N370S, L444P) iPSC neurons after NR treatment. Data ar
SEM (n = 3; Student’s t test).
(I) Mitochondrial membrane potential in GBA-PD (N370S, L444P) iPSC neurons a
mean + SEM (n = 5; two-tailed t test).
(J and K)GBA-PD (N370S, L444P) iPSC-neurons were treated with NR, and the le
was used as a loading control. Quantification is depicted in (K). Data are represe
(L) BNIP3L mRNA levels. Data are normalized on Rplp0 and OAZ1 and expressed
Student’s t test).
2984 Cell Reports 23, 2976–2988, June 5, 2018rons. To further examine the metabolism of exogenous NR, we
treated control and GBA-PD iPSC neurons with 0.5 mM NR
and performed LC-MS-based targeted quantitative metabolo-
mics (Figures 6G and S7J). NR treatment significantly increased
the levels of NAD+ in control and patient cells. In addition, we
found a significant increase of NAM in both groups. On the otherith NR, and mRNA expression levels of mtUPR and mitochondrial biogenesis
ressed as mean + SEM (n = 5; two-tailed t test).
rRNA and tRNA-Leu) to nuclear (b-2M) DNA ratio in untreated samples or after
as mean + SEM (n = 5; two-tailed t test).
and the corresponding untreated control. Data are presented as mean + SEM
images of mitochondria inGBA-PD (L444P) iPSC-derived neurons untreated or
hology in NR treated and untreatedGBA-PD iPSC neurons (G; n = 3; two-sided
e normalized to the corresponding untreated control and presented as mean +
fter NR treatment. Data are normalized to untreated samples and presented as
vels of OPA1, Mfn1, Fis1, and DRP1 were assessed by western blot (J). b-Actin
nted as mean + SEM (n = 5).
as fold changes over untreated. Values are presented as mean + SEM (n = 5;
Figure 7. Nicotinamide Riboside Prevents
Dopaminergic Neuronal Loss and Rescues
Climbing Deficits in GBA-PD Flies
(A) Representative confocal images of adult
Drosophila brains stained with anti-TH antibody.
Control and transgenic flies expressing human wild-
type (WT) or N370S GBA with and without NR
treatment (500 mM for 30 days) are shown (scale bar,
10 mm).
(B) Graphs show DA cell counts in absence or
presence of NR in PPL1 clusters. Data are presented
as mean + SEM (ns, non-significant, n = 8–12 clus-
ters; Kruskal-Wallis with Dunn’s multiple compari-
sons test).
(C) Analysis of climbing ability in adult flies ex-
pressing N370S GBA variants in the presence or
absence of NR (500 mM for 10 days). Data are pre-
sented as mean + 95% confidence interval (n = 50
animals per condition ;Kruskal-Wallis with Dunn’s
multiple comparisons test).hand, levels of NMN, the immediate downstream product of NR,
tended to be higher in NR-treated cells, but this difference was
not statistically significant (Figure 6G).
NR Rescues Motor Deficits in a Drosophila Model of
GBA-PD
To assess the neuroprotective effect of NAD+ precursors in vivo,
we employed a Drosophila model of GBA-PD. Flies expressing
human N370S GBA show increased ER stress, an age-depen-
dent loss of DA neurons accompanied by progressive defects
in climbing activity (Sanchez-Martinez et al., 2016). To explore
neuroprotection, flies expressing wild-type (WT) or N370S GBA
were first raised on normal food, and then adult flies were
aged on food containing NR (500 mM). At 30 days, expression
of N370S GBA caused loss of DA neurons in the protocerebral
posterial lateral 1 (PPL1) cluster. Strikingly, feeding NR signifi-
cantly prevented DA neuronal loss compared to untreated
controls (Figures 7A and 7B). Importantly, NR treatment also
significantly prevented the decline in climbing ability in mutant
N370S GBA flies (Figure 7C).
DISCUSSION
Mounting evidence suggests that mitochondrial dysfunction
plays a key role in PD. Here, we report that neurons from GBA-CePD patients and GBA KO neurons exhibit
mitochondrial dysfunction characterized
by morphological changes, reduced respi-
ration, and increased oxidative stress. As
mitochondrial membrane lipid composition
regulates many of these functions (Aufsch-
naiter et al., 2017) and changes in lipid
metabolism have been observed in GBA-
PD (Scho¨ndorf et al., 2014; Fernandes
et al., 2016; Garcı´a-Sanz et al., 2017), we
examined the mitochondrial sphingolipid
profile of GBA-PD and GBA KO neurons.Lipidomic analysis revealed the absence of a significant accu-
mulation of sphingolipids in patient mitochondria. However, we
observed a significant increase of C16-GlcCer. On the contrary,
the mitochondrial sphingolipid profile of GBA KO neurons was
profoundly altered, with significant accumulation of GlcCer and
glucosylsphingosine. Given the role of sphingolipids in the regu-
lation of mitochondrial properties, substrate accumulation or
even subtle changes in lipid composition of mitochondrial mem-
branes, as observed in patient mitochondria, may interfere with
their biophysical properties and signaling pathways. However,
we are not able to unambiguously define the exact subcellular
localization of these alterations. Even though we have isolated
mitochondria to the highest degree of purity, a small amount of
contamination with lysosomes and ER was still present. The
low degree of non-mitochondrial proteins and the complete
absence of additional lysosomal markers (other than LAMP1)
suggest the residual presence of organelle contact sites in mito-
chondrial preparations. Given the importance of contact sites in
interorganelle communication (Wong et al., 2018), further studies
are needed to investigate the role of distinct sphingolipids in
such inter-organelle communication and mitochondrial
dysfunction.
Overall, we did not observe a gene dosage effect when
comparing mitochondrial function in heterozygous GBA-PD
with GBA KO neurons. Thus, distinctly different mechanismsll Reports 23, 2976–2988, June 5, 2018 2985
likely contribute to mitochondrial dysfunction in these models.
One such mechanism could be the alteration of mitochondria
sphingolipid composition, which we observed in GBA KO, but
not GBA-PD, cells. Interestingly, in other lysosomal storage dis-
eases, the loss of lysosomal enzymatic function leads to sub-
strate accumulation at the ER membranes and subsequent
activation of the UPR (Tessitore et al., 2004). However, despite
significant substrate accumulation in our model, the complete
loss of GCase enzymatic function in GBA KO neurons is not
sufficient to trigger ER stress responses that were instead
observed in heterozygous GBA-PD neurons. This points toward
a key role of gain-of-function mechanisms in ER stress re-
sponses in GBA-PD. On the other hand, GCase deficiency
results in sphingolipid accumulation and mitochondrial dysfunc-
tion including increased mtROS.
GBA-PD neurons showed an imbalance of mitochondrial
shaping proteins DRP1, OPA1, Mfn1, and Fis1 and an increased
ratio of L-OPA1/S-OPA1. As L-OPA1 processing and impaired
DRP1 activity contribute to the dysfunction of mitophagy
(MacVicar and Lane, 2014), our results would suggest an impair-
ment of mitochondrial clearance in GBA-PD. This was further
supported by the reducedmitochondria-lysosome colocalization
and reduced expression of the mitophagy adaptor NIX/BNIP3L.
Unexpectedly, we did not observe a significant increase of mito-
chondrial content in patient neurons. The mitochondrial mem-
brane potential was also preserved in GBA-PD neurons. As
BNIP3L/NIX plays a role in the loss of mitochondrial membrane
potential (Sandoval et al., 2008), reduced levels of BNIP3L in
GBA-PD neurons could explain the lack of decreased mitochon-
drial membrane potential. Taken together, our data suggest an
imbalance of mitochondrial dynamics in GBA-PD neurons that
leads to mitochondrial dysfunction in the absence of accumula-
tion of damaged mitochondria. As mitophagy occurs locally in
distal neuronal axons, we cannot exclude accumulation of
dysfunctional mitochondria within axons (Ashrafi et al., 2014).
Increasing intracellular NAD+ concentrations has been shown
to be protective against age-related metabolic decline and dis-
ease (Rajman et al., 2018; Katsyuba and Auwerx, 2017). NAD+
is a coenzyme for several enzymes, including SIRT1, which reg-
ulates mitochondrial biogenesis, autophagy, and cellular stress
responses (Chang and Guarente, 2014; Prola et al., 2017).
Several mechanisms lead to NAD+ consumption, including
oxidative stress. To examine whether NAD+ decline is involved
inGBA-PD, we have first used targetedmetabolomics and found
that NAD+ levels were maintained in both GBA-PD and GBA KO
iPSC-derived neurons, as well as whole brains from gba/ ze-
brafish. As cellular energy metabolism and the cytosolic
NADH/NAD+ redox state differ in various tissues or different cells
within the same tissue, we have employed a genetically encoded
NADH/NAD+ biosensor for live-cell imaging in iPSC-derived
neurons. GBA-PD neurons showed a significant reduction of
the NAD+/NADH redox state. The reduction of NMNAT2 in
GBA-PD neurons further supports an alteration of NAD+ meta-
bolism in GBA-PD. Besides its role in NAD+ synthesis, NMNAT2
also acts as a chaperone to reduce proteotoxic stress and its
levels decline prior to the onset of neurodegeneration (Ali et al.,
2016). Thus, the reduction of NMNAT2 inGBA-PD neurons could
also explain the increased proteotoxic stress observed in these2986 Cell Reports 23, 2976–2988, June 5, 2018cells. The zebrafish metabolomics data further support an alter-
ation of NAD+metabolism.GBA deficiency led to a significant in-
crease in NMN in zebrafish brains. This strongly suggests
reduced NMNAT activity in the zebrafish brain when lacking
GBA. We were unable to reliably detect NMN at basal conditions
in iPSC-derived neurons, as NMN is a low abundancemetabolite
in cellular extracts. In conclusion, even though we cannot yet
conclude definitively that NAD+ decline occurs in GBA-PD, our
data suggest alterations of NAD+ metabolism in these models.
Given the existence of different cellular NAD+ pools and the rele-
vance ofmitochondrial NAD+ formitochondrial and cellular func-
tion, an important question remains how these NAD+ cellular
pools communicate with each other andmodulate the aging pro-
cess and disease risk.
Here, we report that human iPSC-derived neurons rely on
NAMPT for maintenance of the NAD+ pool, they are responsive
to NAD+ precursors and utilize NRK1 as the main metabolic
pathway to synthetize NAD+ from exogenous NR in aNAMPT-in-
dependent manner. NR administration caused a significant in-
crease of NAD+. Besides NAD+, levels of NAM were also
increased upon NR treatment, suggesting an increase of the ac-
tivity of NAD+ consuming enzymes that convert NAD+ to NAM.
However, we cannot exclude a partial conversion of exogenous
NR into NAM before synthesis to NAD+. Levels of the immediate
downstream product of NR, NMN, tended to be higher in NR-
treated cells, but this difference was not statistically significant.
This would suggest a rapid conversion of NMN into NAD+. In
our model systems, NR ameliorated mitochondrial function and
rescued mitochondrial quality control. We also observed an
increased expression of BNIP3L/NIX after NR treatment. In line
with this, mitochondrial content decreased after 24 hr of NR
treatment, which points toward increased mitophagy. However,
prolonged NR treatment boosted mitochondrial content and
increased TFAM, which underlines the dual role of NAD+ and sir-
tuins inmaintainingmitochondrial biogenesis and quality control.
Furthermore, supporting an increase in mitophagy, NR positively
regulated autophagic function. Importantly, we found that NAD+
supplementation rescues the age-dependent loss of DA neurons
and decline in motor ability in a GBA-PD Drosophila model.
In summary, our study elucidates the mechanisms involved in
GBA-PD and revealsmitochondrial dysfunction as a key driver of
disease. Our findings show that NAD+ precursors ameliorate
GBA-related defects. Among the available NAD+ precursors,
NR may be a valuable therapeutic approach due to its high
bioavailability, minimal toxicity, and evidence of its ability to
cross the blood-brain barrier (Trammell et al., 2016). Future
studies will explore the potential therapeutic benefits of
combining NAD+ boosters with chaperones and GCase activa-
tors (Migdalska-Richards et al., 2016).
EXPERIMENTAL PROCEDURES
Cell Culture
iPSC lines (Table S1) were previously generated and characterized (Scho¨ndorf
et al., 2014).
Generation of GBA Knockout Human iPSCs
CRISPR-Cas9 constructs were generated as described previously (Ran et al.,
2013).
Measurement of Mitochondrial Membrane Potential and mtROS
Neuronswerewashed oncewith Hank’s balanced salt solution (HBSS) (Invitro-
gen) following incubation with 200 nM tetramethylrhodamine methylester
perchlorat (TMRM) (Invitrogen). For measurements of mtROS, cells were incu-
bated with 5 mMMitoSOX Red (Invitrogen). Cytofluorimetric analysis was per-
formed using MACSQuant Analyzer 10 (Miltenyi).
Seahorse XFe96 Metabolic Flux Analysis
OCR was analyzed using an XFe96 Extracellular Flux Analyzer (Seahorse
Biosciences).
NAD/NADH Measurements and Metabolomics
NAD+ levels were measured using the NAD/NADH-Glo Assay Kit (Promega).
NADH levels were measured using the NAD/NADH Assay Kit (Abcam). The
cytosolic NADH/NAD+ redox state of iPSC neurons was measured as
described previously (Hung et al., 2011).
Enzymatic Activities
GCase activity was tested using the intact cell lysosomal b-Glu assay (Sawkar
et al., 2006). Citrate synthase and mitochondrial CI activities were measured
following the protocol reported by Spinazzi et al. (2012).
Drosophila Studies
Transgenic Drosophila lines expressing human WT or N370S GBA were previ-
ously generated (Sanchez-Martinez et al., 2016).
Statistical Analysis
The Statistical Package GraphPad Prism version 7.0b (GraphPad Software,
San Diego, CA) was used to analyze the data. Statistical testing involved a
two-sided Fisher’s exact test, two-tailed Student’s t test, one-way ANOVA
with Bonferroni’s multiple comparison test, or Kruskal-Wallis with Dunn’s mul-
tiple comparisons test, as appropriate. Data are expressed as mean + SEM or
SD as indicated.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2018.05.009.
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Material and reagents 
Nicotinamide riboside hydrochloride was provided by ChromaDex, Inc. and dissolved in water.  
 
Cell culture and treatments 
The iPSC lines used in this study were previously generated from GBA-PD patients and control individuals and 
characterized (Schöndorf et al., 2014). The list of the lines is provided in Table S1. For all iPSC lines, informed 
consent was obtained from patients prior to cell donation using a written form. The protocol was approved by the 
Ethics Committee of the Medical Faculty and the University Hospital Tübingen (Ethikkommission der Medizinischen 
Fakultät am Universitätsklinikum Tübingen). iPSCs were maintained in hESC medium containing knockout DMEM 
(Gibco Life Technologies), 20% knockout serum replacement (Gibco Life Technologies), 1% non-essential amino 
acids (Gibco Life Technologies), 1% penicillin/streptomycin (P/S, Merck Millipore), 1% GlutaMAX Supplement (Gibco 
Life Technologies) and 500 µM β-mercaptoethanol (Sigma-Aldrich) supplemented with 10 ng/ml FGF2 (Peprotech). 
iPSCs were routinely passaged onto MMC-treated CF-1 mouse embryonic fibroblasts (MEF) (Globalstem MTI 
ThermoFisher) with addition of 10 µM Rock inhibitor Y-27632 2HCl (Selleckchem). iPSCs were differentiated into 
dopaminergic neurons according to Kriks et al. (Kriks et al., 2011). Cells were grown for 11 days on Matrigel 
(Corning) in hESC medium. Differentiation was based on exposure to LDN193189 (100 nM, Axon Medchem) from 
days 0–11, SB431542 (10 µM, Selleckchem) from days 0–5, SHH (100 ng/mL, Peprotech), purmorphamine (PMA; 2 
µM, EMD) and FGF8 (100 ng/mL, Peprotech) from days 1–7 and CHIR99021 (CHIR; 3 µM, Axon Medchem) from 
days 3–13. hESC medium was gradually shifted to N2 medium (DMEM/Ham’s F12 , 1% P/S, 1% GlutaMAX and N2 
supplement from Gibco Life Technologies), starting on day 5 of differentiation. On day 11, medium was changed to 
N2/B27 medium containing DMEM/Ham’s F12, Neurobasal medium, N2 and B27 supplement, 1% P/S and 1% 
Glutamax (N2 and B27 supplement; Gibco Life Technologies) supplemented with CHIR (3 µM, until day 13) and 
brain-derived neurotrophic factor (BDNF; 20 ng/ml; Peprotech), ascorbic acid (AA; 200 µM, Sigma-Aldrich), glial cell 
line-derived neurotrophic factor (GDNF; 20 ng/ml; Peprotech), transforming growth factor type β3 (TGFβ3, 1 ng/ml; 
Peprotech), dibutyryl cAMP (0.5 mM; Applichem), and DAPT (10 µM; Selleckchem) for 9 days. On day 20, cells were 
dissociated using Accutase (Sigma-Aldrich) and replated under high cell density conditions on dishes pre-coated with 
15 µg/ml polyornithine and 1 µg/ml laminin in differentiation medium (N2/B27 medium +BDNF, AA, GDNF, dbcAMP, 
TGFβ3 and DAPT). Neurons were maintained in vitro for 45-55 days and then used for experiments. For 
metabolomics after NR treatment, iPSCs were differentiated into dopaminergic neurons using a previously published 
protocol (Reinhardt et al., 2013). iPSC colonies were manually detached 3–4 days after splitting and resuspended in 
hESC medium (without FGF2) supplemented with 10 µM SB431542 (Selleckchem), 1 µM dorsomorphin (Sigma-
Aldrich), 3 µM CHIR 99021, and 0.5 µM PMA. Medium was replaced on day 2 by N2/B27 medium supplemented with 
the same small molecule supplements. On day 4, SB-431542 and dorsomorphin were withdrawn and 150 µM AA 
was added to the medium. On day 6, embryoid bodies were manually triturated and plated on Matrigel-coated 12-
well plates in N2/B27 medium supplemented with CHIR, PMA, and AA. Neural precursor cells (NPCs) were regularly 
split with Accutase at a 1:10 ratio every 5-6 days and used for experiments at passage number 10-12. Expansion 
medium consisted of N2/B27 medium freshly supplemented with CHIR, PMA, and AA. For differentiation into DA 
neurons, expansion medium was changed 2 days after splitting to N2/B27 medium with 100 ng/mL FGF8, 1 µM PMA, 
and 200 µM AA. After 8 days, maturation medium consisting of N2/B27 medium with 10 ng/mL BDNF, 10 ng/mL 
GDNF, 1 ng/mL TGFβ3, 200 µM AA, 500 µM dbcAMP, and 0.5 µM PMA (for 2 more days) was used. One day after 
changing to maturation medium, the cultures were dissociated with Accutase and split at a 1/3 ratio. Cultures were 
analyzed after 2 weeks in maturation medium. 
The quality of iPSCs and iPSC-derived neurons was checked every two months for the presence of mycoplasma. 
Sanger sequencing was performed every three months to check for iPSC line identity. The quality of neuronal 
cultures was checked by confirmation of the presence of neuronal and dopaminergic markers by immunostaining for 
β-III Tubulin and TH. Only neuronal cultures that passed quality checks were used for further experiments. iPSC-
derived neurons were treated with 0.5 mM NR (ChromaDex, Inc) or 1 µM PJ34 (Tocris) for 24 or 48 h (where 
indicated). The following reagents were used: 0.5 mM ß-nicotinamide mononucleotide  (NMN; Sigma-Aldrich), 0.5 
mM nicotinamide  (NAM, Sigma-Aldrich), 1 nM FK866 (Sigma-Aldrich), 100 nM EX527 (Tocris). Appropriate vehicle 
control was used. 
 
Generation of GBA knockout human iPSCs with CRISPR-Cas9 
CRISPR-Cas9 constructs used in this study were generated as described by Ran et. al (Ran et al., 2013). The 
pSpCas9(BB)-2A-Puro plasmid containing the sgRNA scaffold and a puromycine resistance under the U6 promoter 
was purchased from Addgene (Addgene plasmid #48139). sgRNAs targeting exon 3 and exon 4 of the GBA locus 
with low predicted off target effects were designed using the CRISPR Design Tool (http://tools.genome-
engineering.org) and purchased at Metabion International AG. sgRNA sequences: GBA Exon 3 top 
TACACGCAGTGGGCGACGGA; GBA Exon 3 bottom TCCGTCGCCCACTGCGTGTA; GBA Exon 4 top 
GGAACTTCTGTTCTGGCTGC; GBA Exon 4 bottom GCAGCCAGAACAGAAGTTCC. Successful integration of the 
sgRNAs in the pSpCas9 plasmid was confirmed by Sanger sequencing using a primer pairing in the U6 promoter 
region. iPSCs were dissociated using 0.02% EDTA and 1x105 cells were nucleofected with 7 µg sgRNA containing 
pSpCasp9 plasmids targeting exon 3 and exon 4 of the GBA gene using an Amaxa Nucleofector II (program B16). 
After nucleofection, iPSCs were replated onto MEF-coated dishes in hESC medium containing 10 µM ROCK inhibitor 
without P/S. The next day the medium was replaced with mTeSR (StemCell Technologies) containing 0.5 µg/ml 
puromycin (Sigma-Aldrich) for 48 h. After 5-7 days, single colonies were manually picked and transferred on MEF-
coated plates for further expansion. To check for Cas9-induced double-strand breaks, DNA was isolated and the 
exon 1-5 region of the GBA gene was amplified. The resulting PCR product was purified and the exon 3-4 region 
was amplified to check for genomic deletions on a 1.5% agarose gel. Genomic deletions in GBA knockout iPSCs 
were confirmed by Sanger sequencing. The following primers were used: 
 
Primer for GBA exon 3 and 4 amplification and sequencing (5’-3’) 
GBA Exon 1-5 
  
FW CCTAAAGTTGTCACCCATAC 
RV AGCAGACCTACCCTACAGTTT 
GBA Exon 3 
  
FW ATGTGTCCATTCTCCATGTC 
RV GGTGATCACTGACACCATTT 
GBA Exon 4 
  
FW GGTGTCAGTGATCACCATGG 
RV ACGAAAAGTTTCAATGGCTCT 
 
 
The off-target loci with the highest prediction scores for each sgRNA were sequenced by Sanger sequencing. 
 
Sequencing primers for off-target effect (5’-3’) 
CAMTA2  FW TTCCGTCCTCCTCCCCC 
RV GAGTGGTGGTCCCAGGAGAA 
UBA7  FW TCCCTGAACCTCAGCCTGTC 
RV AGCCTCAAGGGGTGGGGTTA 
P2RX2  FW CGTGTTCAGCATCATCACCAGG 
RV AGAGGTCACTGAGGCATTAGC 
TMEM31 
 
FW ATGGCAGCATACTCCAGCAA 
RV TGAACGCTGCCTGACCAATTA 
GGCX 
 
FW CAGGCAGGGATCTCGTTGTG 
RV CAATACCAGGAAGCAAGGGCT 
SYT7 
  
FW TCTCCCTTCCTTCTCAGGGG 
RV AAATCTGCCGTCTCCAAGGG 
PLEKHH2 
  
FW ACTCAGAGCTGGTGTTTGGC 
RV GAGGCTCAATCTGACTGACTGC 
PLEKHM2 
  
FW ACTGCCTAGGACCACTGACG 
RV GGGAGGCAAGCATAGTGTCT 
LOC100505795 
  
FW ACAACAGACAGAGCGGCAAG 
RV ATCTTTCTTGCCTCGAGGGTG 
SPTB 
  
FW CAGAAGGGGCAGTCCCAAGA 
RV GCCCCACCTGCTACTTCTTTT 
FGFR1OP 
  
FW CACCAGTGTTGCTGCTTTGTG 
RV TGACAGCGCCTGATCACTTC 
ZKSCAN1 
  
FW GGCTGCGGCCAGAAATAAAC 
RV GTTTCAACGTCTGTGCCCTG 
 
 
Measurement of mitochondrial membrane potential  
For measurement of mitochondrial membrane potential, neurons were split at a concentration of 2x105/well on 96-
wells pre-coated with Matrigel. Cells were kept in N2 medium for 24 h. Cells were washed once with HBSS 
(Invitrogen) following incubation with 200 nM Tetramethylrhodamine Methylester Perchlorat (TMRM) (Invitrogen) in 
HBSS with 1% BSA for 30 min at 37°C. Cells were then washed twice with HBSS, detached using Accumax 
(Invitrogen) and kept in HBSS with 1% BSA (Sigma-Aldrich) for FACS analysis using MaxQuant Analyzer 10 
(Miltenyi Biotec). Analysis was performed using the MACSQuantify 2.6 software (Miltenyi Biotec). 
 
Measurement of mitochondrial ROS  
For measurement of mtROS, neurons were split at a concentration of 2x105/well on 96-wells pre-coated with Matrigel. 
iPSC-derived neurons were pre-incubated with N2 medium for 48 h. Next, cells were washed once with HBSS, 
incubated with 5µM MitoSOX Red (Invitrogen) for 30 min at 37°C, washed twice with HBSS, trypsinized and 
resuspended in 200µl of HBSS and 1% BSA. Cytofluorimetric analysis was performed using MACSQuant Analyzer 
10 (Miltenyi BIotec).  
Seahorse XFe96 Metabolic Flux Analysis  
Oxygen consumption rate was analyzed using an XFe96 Extracellular Flux Analyzer (Seahorse Biosciences). iPSC-
derived neurons were plated on V3-PS XF plates (Seahorse Biosciences) at a density of 5 x104/well  per well and 
grown in N2 medium for 48 h before the experiment. Respiration was measured after sequential injection of 1µM 
oligomycin, 5µM carbonyl cyanide p-trifluoromethoxyphenylhydrazone (CCCP) and 1µM rotenone and 1µM 
Antimycin A (all from Sigma-Aldrich). After each injection, OCR was measured for 2 minutes, the medium was mixed 
for 2 min, and then respiration was measured again for 2 minutes. Values were normalized to cell number by 
counting DAPI stained nuclei using a high-content cell analyzer (BD Bioscience, Pathway 855). 
 
Western blot 
Proteins were extracted using Tris-buffered Saline (TBS) with 0.5% NP40 lysis buffer containing protease and 
phosphatase inhibitors (Roche) on ice following centrifugation at 14.000 rpm and 4°C for 15min. The protein 
concentration of the supernatant was determined by BCA (Pierce). In total, 15–30 µg of the protein lysate was loaded 
on a 7% to 15% polyacrylamide gel and transferred on a PVDF membrane (Millipore). Isoforms of OPA1 were 
resolved on a 7% polyacrylamide gel and corresponding higher (~100kDa) and lower (~80kDa) bands were used for 
densitometric analysis to obtain the L-OPA1/S-OPA1 ratio. Blots were blocked with 5% milk or 5% BSA in TBS + 
0.1% Tween 20 (TBST) and incubated with primary antibodies in blocking solution (Western Blotting Reagent, 
Roche) overnight at 4 °C. This step was followed by incubation with corresponding HRP-conjugated secondary 
antibodies (Sigma-Aldrich) for 1 h at room temperature. Visualization of proteins was done by using Amersham ECL 
Western Blotting Detection Reagent and Amersham Hyperfilm (both GE healthcare). Densitometric analysis of 
proteins was performed by ImageJ software.  
 
Immunofluorescence  
Cells were fixed in 4% paraformaldehyde (PFA) in PBS (w/v) for 10 min, rinsed with PBS and blocked by 10% 
normal goat or donkey serum (NGS/NDS) in PBST (PBS + 0.1% TritonX-100) for 60 min. Cells were then incubated 
with primary antibodies in 10% NGS/NDS in PBST over night at 4°C following 1h incubation at 24°C with appropriate 
Alexa488/568/647 coupled secondary antibodies (Invitrogen). Cell nuclei were stained with Hoechst and final images 
were acquired with a Zeiss Imager Z1 with Apotome (Carl Zeiss) microscope using a 63x 1.4NA plan-apochromat oil 
objective. For mitochondrial lysosomal co-localization analysis, Z-stack pictures of single cells were obtained with a 
Leica TCS SP8 X confocal microscope (Leica Biosystems) using a 63x 1.4NA plan-apochromat oil objective. Images 
were processed in ImageJ (NIH) and brightness/contrast was adjusted equally.  
 
Zebrafish experiments 
Zebrafish were raised at a density of 20 individuals per tank until 12 weeks of age. Animals were then culled, brains 
extracted and flash frozen. Samples were stored at -80 °C until use. Each animal was genotyped using primers FW 5’ 
AAAGCAGCACGATATGTCCA and RV 5’ ATGTCATGGGCGTAGTCCTC as previously described (Keatinge et al., 
2015).  
 
 
 
ImageStream  
Cells were fixed in 1% PFA, permeabilized and blocked in 10% FBS/0.1%Triton X solution. Intracellular staining was 
performed with anti-rabbit TOMM20 and anti-mouse LAMP1 antibodies. Staining was detected with Alexa Fluor 
488/568 secondary antibodies (Invitrogen). Images were acquired on an Amnis ImageStream 100 imaging flow 
cytometer (EMD Millipore) with a 40x or 60x magnification with a minimum of 10,000 events acquired per sample. 
Single stained samples were used to create a compensation matrix. Double positive cells were gated, and Bright 
Detail Similarity Feature was applied to calculate co-localization score between TOMM20 and LAMP1 signals with 
Amnis IDEAS software (EMD Millipore). Cells treated with 10µM CCCP for 24 hours were used as positive control.  
 
NAD/NADH measurements and metabolomics  
To measure NAD+ levels, 4x105 iPSC-derived neurons were harvested and analysed using the NAD/NADH-Glo™ 
Assay Kit (Promega) following the manufacturer´s instructions. To measure NADH levels, 1×106 iPSC-derived 
neurons were harvested and the NAD/NADH Assay Kit (Abcam) was used following the manufacturer’s instructions. 
For cell metabolomics, cells were differentiated onto 6-well plates, washed once with ice-cold PBS and snap frozen 
on dry ice. The plates were kept at -80°C until shipment. Metabolomics analysis was performed at the Southeast 
Center for Integrated Metabolomics (SECIM) at Sanford-Burnham-Prebys Medical Discovery Institute, following 
protocols as defined on the Metabolomics Workbench. For zebrafish metabolomics, frozen zebrafish brains from 
gba+/+, gba+/- and gba-/- (each n=6) were received on dry ice and lyophilized to dryness overnight. Groups of three 
freeze-dried brains were pooled for each sample. For oxidized nucleotides, cell slush on ice was vortexed with 200 
µL of 1 M perchloric acid and brought up to a volume of 400 µL with deionized water. A 100 µL aliquot of 
homogenate was used to measure reduced pyridine nucleotides. The homogenate was centrifuged at 14,000 rpm at 
10 °C for 5 minutes. Then, the supernatant was neutralized with 100 µL of 1 M ammonium formate. Oxidized 
nucleotides were analyzed using a Dionex 3000 HPLC/Thermo Scientific triple quadrupole mass spectrometer, and 
quantified according to calibration curves obtained from neat standards using 18O2-NMN and 18O2-NAD as internal 
standards. For reduced nucleotides, cell slush on ice was vortexed with 200 µL of NaOH and 8 mL of 5 M NaOH, 
and brought to a volume of 400 µL with deionized water. 200 µL aliquot of homogenate was used to measure 
reduced pyridine nucleotides. The homogenate was centrifuged at 14,000 rpm at 10 °C for 5 minutes. Then, the 
supernatant was analyzed using a Dionex 3000 HPLC/Thermo Scientific triple quadrupole mass spectrometer. 
NADH and NADPH in unknown samples were quantitated according to calibration curves obtained from neat 
standards using 18O2-NADH as an internal standard. 
 
Cytosolic NADH/NAD+ redox state  
The cytosolic NADH/NAD+ redox state of iPSC-derived neurons was measured following a protocol previously 
described by Hung et al (Hung et al., 2011, Hung and Yellen, 2014). iPSC-derived neurons were transfected with 
GW1-Peredox-mCherry (Addgene #32380) using Viafect transfection reagent (Promega). Cells were chosen based 
on neuronal morphology and imaged live in a humidified chamber with 5% CO2 and 37°C using a Zeiss Axio 
Observer Z1 (Carl Zeiss) microscope with a 63x 1.4NA plan-apochromat oil objective. For final NADH/NAD 
quantification, Peredox signal was normalized to mCherry signal using Image J.  NR-treated cells were used as 
positive control. 
 
Quantitative RT-PCR 
mRNA was isolated using a RNA isolation kit (Qiagen). Following the reverse transcription reaction using the 
QuantiTect Reverse Transcription kit, quantitative PCR reaction was performed using QuantiTect SYBR GREEN I kit 
(Qiagen) and monitored with a Viia7 Real time PCR system (Applied Biosystems). The expression level of each gene 
was normalized to the housekeeping genes ribosomal protein large P0 (Rplp0) and ornithine decarboxylase 
antizyme 1 (OAZ) as indicated. Fold-changes in gene expression were calculated using the 2-DDCT method, based on 
biological reference samples and housekeeping genes for normalization.  
 
Primers used for quantitative PCR (5’-3’) 
OAZ 
  
FW AGCAAGGACAGCTTTGCAGTT 
RV ATGAAGACATGGTCGGCTCG 
RPLP0 
  
FW CCTCATATCCGGGGGAATGTG 
RV GCAGCAGCTGGCACCTTATTG 
HSP60  
  
FW TGACCCAACAAAGGTTGTGA 
RV CATACCACCTCCCATTCCAC 
TFAM  
  
FW GCTTGGAAAACCAAAAAGACCTCGT 
RV GTCTTCAGCTTTTCCTGCGGTG 
PGC1a 
  
FW TGAAAAAGCTTGACTGGCGT 
RV GTCACTGCACCACTTGAGTC 
GBA 
  
FW ACCCTAGGGGAGACACACCG 
RV AATTGGGTCCTCCTTCGGGG 
Sirt1 
  
FW GAGCTGGGGTGTCTGTTTCA 
RV TTTGGATTCCCGCAACCTGT 
XBP1S FW TGCTGAGTCCGCAGCAGGTG 
RV GCTGGCAGGCTCTGGGGAAG 
BNIP3L FW CAGCAGGGACCATAGCTCTC 
RV TCCTTGGGTGGAATGTTTTC 
NAMPT FW ATCCTGTTCCAGGCTATTCTGT 
RV CCCCATATTTTCTCACACGCAT 
NMNAT2 
FW GATCCTGCTGCTGTGTGGTA 
 
RV ACCACCACAATCCCAAAGTC 
NMNAT1 FW AAAGAAATCCCTAGAGCCAAAA 
RV TCCAGCCCGAGTAACACATA 
NMNAT3 FW CACGACCCAAAAGGTTACATC 
RV TGACAGCATCGGGAATCA 
NMRK1 FW GGATGGAAAGCGCAAGACAC 
RV ATGGCCATCAAAGTATCCCG 
NMRK2 FW ACCGTCCCGTATGAAGAGTG 
RV AGAGCTCCTCTCGGGACTTC 
 
Mitochondrial DNA content  
Genomic and mitochondrial DNA (mtDNA) was isolated using the Blood and Tissue DNA isolation Kit (Qiagen) 
following the manufacturer’s instructions. Real-time quantification of DNA targets was performed using the 
QuantiTect SYBR Green Kit (Qiagen) and respective primers (see list below for primers used) on a ViiA7 Real-Time 
PCR System (Applied Biosystems). Fold changes of mtDNA abundance were calculated using the 2-DDCT method and 
normalized to the biological reference sample and the genomic housekeeping gene beta-2-microglobulin (b-2M).  
 
Primers for mitochondrial content quantification (5’-3’) 
tRNALeu FW CACCCAAGAACAGGGTTTGT 
  RV TGGCCATGGGTATGTTGTTA 
β2-microglobulin  FW TGCTGTCTCCATGTTTGATGTATCT 
  RV TCTCTGCTCCCCACCTCTAAGT 
16S rRNA  FW GCCTTCCCCCGTAAATGATA 
  RV TTATGCGATTACCGGGCTCT 
 
 
Enzymatic activities 
GCase enzymatic activity was tested using the intact cell lysosomal β-Glu assay with slight modifications (Sawkar et 
al., 2006). iPSC-derived neurons were plated onto Matrigel-coated 48-well plates in differentiation medium (5 x104 
cells/well). For CBE-sensitive GCase assay, the cells were pre-incubated for 30 min at room temperature in 
McIlvaine Buffer (0.1 M Citrate/0.2 M Phosphate) pH 6.0 containing 5 nM AMP-DNM N-(5-adamantane-1-yl-methoxy-
pentyl)-deoxynojirimycin). After incubation with the inhibitor, 4-methylumbelliferyl-β-D-glucopyranoside (MUB-Glc, 
Glycosynth) was added at a final concentration of 3 mM. The reaction mixtures were incubated at 37 °C under gentle 
shaking. The fluorescence was recorded after transferring 20 µl of the reaction mixtures to a microplate and adding 
180 µl of 0.25 M glycine, pH 10.7. Citrate synthase and mitochondrial complex I activities were measured from 
mitochondrial-enriched fractions following the protocol reported by Spinazzi et al. (Spinazzi et al., 2012). Complex I 
data were normalized to citrate synthase activity.  
 
Autophagy studies 
Where indicated, cells were treated with NH4Cl (20 mM) and leupeptin (200 µM) (EMD, Millipore) for 4 h. LC3-II and 
LC-I levels were quantified by densitometry and normalized to β-actin. LC3 flux was quantified as the change in LC3-
II levels in the presence and in the absence of lysosomal inhibitors. 
 
Mitochondrial isolation and lipidomic analysis 
The mitochondrial isolation was performed with the Qproteome® Mitochondria Isolation Kit (Qiagen) according to the 
supplier's protocol. iPSC-derived neurons were washed with cold PBS, lysed, and centrifuged at 1,000 g for 10 
minutes at 4°C. The supernatants were collected (cytosolic fraction), and the pellets were washed twice with cold 
PBS, resuspended and sheared via passage 20-30 times through a 26-gauge needle. The lysates were then 
centrifuged at 1,000 x g for 10 minutes at 4°C, and the supernatant fractions, containing the mitochondria, were 
centrifuged again at 6,000 x g for 10 minutes at 4°C. After determining the protein concentration, purity was 
confirmed by Western blot. Mitochondrial fractions were lyophilized and subjected to lipidomic analysis. Analyses of 
all sphingolipids (total and mitochondrial) were performed by high-performance liquid chromatography mass 
spectrometry (LC-MS/MS) methodology at MUSC Lipidomics Shared Resource at the Medical University of South 
Carolina as previously described (Bielawski et al., 2009). Lipids were extracted from frozen cell pellets or 
mitochondrial extracts from iPSC-neurons. Quantitative analyses of sphingolipids are based on eight-point calibration 
curves generated for each target analyte. The synthetic standards along with a set of internal standards are spiked 
into an artificial matrix; they are then subjected to an identical extraction procedure as the biological samples. These 
extracted standards are then analyzed by the HPLC/MS/MS or SFC/MS/MS system operating in positive MRM mode 
employing a gradient elution. The equipment consisted of a Thermo Scientific Accela Autosampler and Quaternary 
Pump coupled to a Thermo Scientific Quantum Access triple quadrupole mass spectrometer equipped with an ESI 
probe operating in the multiple reaction monitoring positive ion mode. Separation of Glu-Cer was performed by SFC-
MS/MS analyses employing the same mass spectrometer tuned and optimized for the Waters UPC 2 system. 
Chromatographic separations were obtained utilizing a carbon dioxide gas and 1 mM ammonium formate in 0.2% 
formic acid in methanol mobile phase. Chromatographic separations were obtained under a gradient elution for both 
assays. Peaks for the target analytes and internal standards are recorded and processed using the instrument’s 
software system. Plotting the analyte/internal standard peak area ratios against analyte concentrations generates the 
analyte specific calibration curves. Any sphingolipid for which no standards are available are quantitated using the 
calibration curve of its closest counterpart. Lipid levels were expressed as pmol lipid level/ nmol Pi. The analysis was 
repeated from independent differentiation onsets (n for each experiment is indicated in figure legend).  
 
Lentivirus-mediated shRNA 
The Mission lentiviral plasmids encoding turbo GFP (SHC003), non-targeting control shRNA (SHC016) and NRK1 
shRNA (TRCN0000160469, TRCN0000160349) in pLKO.1-puro vector backbone were used (from Sigma-Aldrich). 
Lentiviral stocks were prepared by calcium phosphate transfection and the packaging vectors pLP1, pLP2 and 
pLP/VSVG using the ViraPower HiPerform T-REx Gateway Expression System (Invitrogen). Supernatants were 
collected over 48 to 60 h and virus with minimal MOI 5x 105 IFU/ml was concentrated and used to infect cells. 
 
Transmission electron microscopy and analysis of mitochondrial morphology  
After washing with 0.1 M PB cells were processed in 1% osmium tetroxide / 6.85% sucrose in 0.1 M PB for 1 h. 
Samples were dehydrated using increasing ethanol concentrations (20%-100%) for each 10 minutes, with incubation 
steps using 1% uranyl acetate in 70% ethanol for 1h in between. Samples were then incubated twice for 5 min with 
propylene oxide before embedding in Durcupan (Sigma-Aldrich) overnight. Ultrathin sections (60 nm) were cut and 
stained with lead citrate (Reynolds). Images were taken with a TEM LEO 906 microscope (Zeiss) with the sharp-eye 
2k CCD camera and processed with ImageSP (Tröndle, Germany). Morphometric classification of mitochondrial 
cristae morphology on EM pictures was performed blindly on at least 50 cells per condition from independent 
experiments. Individual cells were scored for normal (lamellar) or ballooned/swollen cristae (disorganized). 
Mitochondrial major diameter was measured blindly using NIH Image J software.  
 
Drosophila studies 
Transgenic Drosophila lines expressing human wt or N370S GBA were previously generated (Sanchez-Martinez et 
al., 2016). Flies were raised under standard conditions at 25 °C on agar, cornmeal and yeast food which was re-
liquefied and supplemented with NR solution to a final concentration of 500 µM or an equivalent volume of vehicle 
(water). Climbing assay was performed as previously described (Greene et al., 2003). Drosophila brains were 
dissected from 30-day old flies and immunostained with anti-tyrosine hydroxylase. Brains were imaged with an 
Olympus FV1000 confocal with SIM-scanner on a BX61 upright microscope using a 63X oil 0.95 NA objective. 
Tyrosine hydroxylase-positive neurons were counted under blinded conditions. 
 
Statistical analysis 
The Statistical Package GraphPad Prism version 7.0b (GraphPad Software, San Diego California USA) was used to 
analyze the data. Statistical testing involved two-sided Fisher’s exact test, two-tailed Student’s t-test, One-way Anova 
with Bonferroni's multiple comparison test, Kruskal-Wallis with Dunn’s multiple comparisons test as appropriate. 
Experiments have been repeated independently (n=independent differentiation onsets) and each genotype has been 
analysed in technical duplicate or triplicate for each independent experiment (as indicated in the figure legend). Data 
from individual genotypes have been pooled for each experiment and the mean from independent differentiations 
has been calculated for data representation. Data are expressed as mean + SEM or SD as indicated.  
 
Antibodies 
 
Antibody Host Dilution Use Brand Catalog Nr. 
β-Actin mouse 1:20000 WB Sigma Aldrich A5441 
Cathepsin L mouse 1:1000 WB BD Bioscience 611084 
Drp1 mouse 1:750 WB Santa Cruz Biotechnology sc-271583 
eif2-alpha rabbit 1:1000 WB Cell Signaling #9722 
Fis1 rabbit 1:1000 WB Alexis ALX-210-907 
GAPDH mouse 1:20000 WB Meridian Life Science H86504M 
GBA mouse 1:500 WB Abnova H00002629-M01 
GBA N17 goat 1:2000 WB Santa Cruz Biotechnology sc-30844 
GRP78/BiP rabbit 1:3000 WB Sigma Aldrich G9043 
HSP90 rabbit 1:20000 WB Enzo Life Sciences ADI-SPA-836 
KDEL mouse 1:500 WB Santa Cruz Biotechnology sc-58774 
Lamp1 mouse 1:40 ICC DSHB H4A3 
Lamp1 mouse 1:50 FCM DSHB H4A3 
LC3 rabbit 1:1000 WB Cell Signalling #2775 
MAP2 chicken 1:3000 ICC Abcam ab5392 
MFN1 mouse 1:1000 WB Abcam ab57602 
NRK1 mouse 1:200 WB Santa Cruz Biotechnology sc-398852 
Opa1 mouse 1:1000 WB BD Bioscience 612606 
PARP1 rabbit 1:4000 WB Cell Signaling #9542 
PERK rabbit 1:500 WB Santa Cruz Biotechnology sc-13073 
Phospho-eif2-alpha rabbit 1:1000 WB Cell Signaling #9721 
Phospho-PERK rabbit 1:500 WB Santa Cruz Biotechnology sc-32577 
TOM20  rabbit 1:50 FCM Santa Cruz Biotechnology sc-11415 
TOM20 rabbit 1:2000 ICC Santa Cruz Biotechnology sc-11415 
TOM70 rabbit 1:8000 WB ProteinTech 14528 
Total OXPHOS human 
WB antibody cocktail  mouse 1:1000 WB Abcam ab110411 
TUBB3 mouse 1:1000 ICC Biolegend 801201 
Tyrosine Hydroxylase mouse 1:100 IHC Immunostar Inc. 22491 
Tyrosine Hydroxylase rabbit 1:500 ICC Pel-Freeze Biologicals P40101-150 
Vinculin  mouse 1:3000 WB Sigma Aldrich V9131 
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Figure S1, related to Figure 1.  
Mitochondrial function in GBA-PD iPSC-neurons. (A) TEM of mitochondrial morphology of healthy 
control (CTRL), GBA-PD (N370S) and gene corrected (GC) iPSC-derived neurons. Representative TEM 
images of mitochondria are shown (scale bar 500 nm). (B) Mitochondrial respiration in healthy control 
(CTRL) and GBA-PD (N370S, L444P, RecNcil) iPSC-derived neurons. Oxygen consumption rates (OCR) 
were measured over time after the sequential addition of oligomycin, CCCP and rotenone/antimycin A in 
iPSC-neurons. Values for basal OCR, ATP-linked OCR, maximal OCR, and spare respiratory capacity 
(SRC) are shown. Data are represented as mean + SD (n=5-7; two-tailed t-test). (C, D) Western blot 
analysis of the level of OXPHOS complexes in isogenic GBA-PD and GC iPSC-neurons. Representative 
blot is shown in (C) and the quantification is shown in (D). Data are represented as a fold ratio of GBA-PD 
to GC controls + SEM (n = 7). (E) Representative TEM images of mitochondrial morphology of GBA-PD 
(N370S and L444P) iPSC-neurons (scale bar 500 nm). (F) Quantification of mitochondrial cristae 
morphology in GBA-PD (N370S, L444P) iPSC-derived neurons (n=3; two-sided Fisher’s exact test). (G) 
Mitochondrial respiration in GBA-PD (N370S, L444P, RecNcil) iPSC-derived neurons. Oxygen 
consumption rates (OCR) were measured over time after the sequential addition of oligomycin, CCCP and 
rotenone/antimycin A in iPSC-neurons. Values for basal, maximal, and ATP-linked OCR are shown. Data 
are represented as mean + SD (n=8; two-tailed t-test). (H) Mitochondrial ROS (mtROS) levels were 
determined by FACS using MitoSOX Red in GBA-PD (N370S, L444P, RecNcil) and GC controls iPSC-
neurons. Data are normalized to GC and represented as mean + SEM (n=5; two-tailed t-test). (I) 
Enzymatic assays for complex (CI) activity from human mitochondrial extracts enriched from isogenic 
GBA-PD (N370S, L444P) and normalized to corresponding GC iPSC-neurons. Data are expressed as 
mean + SEM (n=5; two-tailed t-test). (J) Purification of mitochondria from iPSC-derived neurons. 
Validation of purity of mitochondria was performed by Western blot. Twenty micrograms of each sample 
(lanes 1-4: purified mitochondria; lanes 5-8: total cell lysate) from GC, GBA-PD, and two GBA KO lines 
were subjected to western blotting against mitochondrial complex proteins (IV-COX II, I-NDUFB8), 
cytosolic protein (HSP90), nuclear protein (PARP1), ER protein (KDEL), lysosomal proteins (GCase, 
Cathepsin L, LAMP1). Long exposures were used to detect contamination with non-mitochondrial proteins. 
Red arrows indicate the low amount of contamination with the ER and lysosomal proteins, KDEL and 
LAMP1.  		

Figure S2, related to Figure 2. 
ImageStream analysis of lysosomal/mitochondrial colocalization. (A) Representative ImageStream 
images showing TOM20/LAMP1 in GBA-PD iPSC-neurons and corresponding isogenic controls. Cells 
treated with 10 µM CCCP for 24 hours were used as positive control. (B) Bright detail similarity (BDS) 
score is indicated as quantification. Data are represented as mean + SD (n=4, two-tailed t-test). BDS for 
CCCP-treated samples, mean=2.1±0.2. 	

Figure S3, related to Figure 3 and Figure 4.  
Mitochondrial function in GBA knockout (KO) human iPSC-derived neurons. (A) Schematic diagram 
showing the wild-type (wt) GBA gene and the targeting strategy for the generation of GBA KO human 
iPSCs. Two single guide RNAs (sgRNAs) were designed to introduce DNA double-strand breaks in exon 3 
and 4 in the GBA gene resulting in a shift of open reading frame and consequently an early stop codon. 
Grey boxes represent exons and blue and green areas binding sequences of the corresponding sgRNA. 
(B) Genomic cleavage analysis of the GBA locus by PCR and agarose gel electrophoresis. (C) Schematic 
representation of the genomic deletion at the GBA locus showing gene sequence of wt GBA gene (exon 3 
and exon 4, upper lane) and the GBA knockout (GBA KO) allele (bottom lane) after successful double-
strand DNA cleavage with the CRISPR-Cas9 system. (D) GBA mRNA levels in control iPSCs (line C2) 
and GBA-PD (line PD3) iPSC-derived neurons and corresponding isogenic GBA KO clones (C2, clones 
#18 and #20; PD3, clones #4 and #16, respectively). Data are normalized on Rplp0 and represented as 
mean + SEM (n=3; two-tailed t-test). (E) Left panel, representative Western blots showing the absence of 
GCase in individual clones of GBA KO neurons derived from two independent control human iPSC lines 
(C1.2, knockout clones #2 and #7; C2, knockout clones #18 and #20) or GBA-PD iPSCs with N370S GBA 
mutation (PD3, knockout clones #4 and #16). Right panel, representative Western blot with an antibody 
targeting the N-terminus of GCase (N17) showing the absence of truncated protein in GBA KO iPSC-
derived neurons. (F) GCase activity in GBA KO and isogenic control iPSC-neurons. Data are represented 
as mean + SEM (n=3; two-tailed t-test). (G-I) HPLC-MS/MS measurement of total sphingolipids in CTRL 
and GBA KO iPSC-derived neurons. (G) Glucosylceramide species and glucosylsphingosine. (H) 
Ceramide species, dhC16-Cer, dhSphingosine, sphingosine, and sphingosine 1-phosphate. (I) 
Galactosylceramide species and galactosylsphingosine. Data are normalized to inorganic phosphate (Pi) 
and represented as mean + SEM (n=4; two-tailed t-test). (J) Mitochondrial respiration in isogenic GBA-PD 
(N370S), gene corrected (GC) controls and GBA KO iPSC-derived neurons. Oxygen consumption rates 
(OCR) were measured over time after the sequential addition of oligomycin, CCCP and 
rotenone/antimycin A in iPSC-neurons. Values for basal OCR, ATP-linked OCR, maximal OCR, and spare 
respiratory capacity (SRC) are shown. Data are represented as mean + SD (n=5-7; one-way ANOVA). (K) 
Complex I (CI) activity was assessed in mitochondrial extracts from isogenic GBA-PD, GC and GBA KO 
iPSC-neurons. Data are represented as mean + SEM (n=5; one-way ANOVA). (L) Western blot depicting 
the ER stress related protein BiP in GBA KO iPSC-derived neurons and corresponding isogenic controls. 
(M) NMNAT2 mRNA levels in isogenic CTRL and GBA KO iPSC-neurons. Data are normalized to the level 
of the housekeeping genes Rplp0 and OAZ and expressed as fold change over CTRL. Data are 
expressed as mean + SEM (n=5; two-tailed t-test). (N) The NAD+/NADH redox state was measured in 
CTRL and GBA KO iPSC-derived DA neurons using the biosensor Peredox. Results are presented as 
mean + SEM (n=5; two-tailed t-test).  	
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Figure S4, related to Figure 5.  
LC/MS-based targeted metabolomics in GBA-PD, isogenic control and GBA KO iPSC-derived 
neurons. GBA-PD (N370S, L444P), isogenic GC and GBA KO (clones #4 and #16) iPSCs were 
differentiated into DA neurons for 55 days and pyridine and adenine nucleotides were measured using 
HPLC coupled to mass spectrometry. Data are expressed as mean + SEM (GBA-PD and GC n= 5-7; GBA 
KO, n=4). 	
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Figure S5, related to Figure 5.  
LC/MS-based targeted metabolomics in zebrafish brains. Pyridine and adenine nucleotides were 
measured using HPLC coupled to mass spectrometry in brains of 2-month old gba+/+, gba+/- and gba-/- 
zebrafish. Data are expressed as mean + SEM (n=3; two-tailed t-test). 	

Figure S6, related to Figure 5.  
Nicotinamide riboside treatment in GBA-PD and GBA KO iPSC-neurons. (A) Control iPSC-derived 
neurons were treated with 0.5 mM nicotinamide (NAM), 0.5 mM nicotinamide mononucleotide (NMN), 0.5 
mM nicotinamide riboside (NR) or vehicle (Veh) and NAD+ levels were measured using a NAD+ cycling 
assay. Results are normalized to vehicle-treated and represented as mean + SEM (n=3; two-tailed t-test 
compared to vehicle-treated). (B) GBA-PD iPSC-derived neurons were treated with NR and NAD+ levels 
were measured using a NAD+ cycling assay. Results are normalized to untreated and represented as 
mean + SEM (n=3; two-tailed t-test). (C) iPSC-derived neurons were treated with NR and NADH levels 
were measured with a NAD+ cycling assay. Results are normalized to untreated and represented as mean 
+ SEM (n=3; two-tailed t-test compared to untreated). (D) GBA-PD iPSC-derived neurons were treated 
with NR plus 100 nM EX-527 for 24 hours and mtDNA content was assessed by qRT-PCR as 
mitochondrial (16S rRNA and tRNA-Leu) to nuclear (ß-2M) DNA ratio. Data are normalized to untreated 
and expressed as mean + SEM (n=5; two-tailed t-test). (E) GBA KO iPSC-derived neurons were treated 
with NR and NAD+ levels were measured using a NAD+ cycling assay. Results are normalized to 
untreated and represented as mean + SEM (n=3; two-tailed t-test compared to untreated). (F) NR 
treatment rescues mitochondrial morphological alterations in GBA KO iPSC-derived neurons. GBA KO 
iPSC-derived neurons (clones #2, #7 and clones #18, #20) were treated with NR and mitochondrial 
morphology was assessed by TEM. Mitochondria were counted from at least 50 individual cells and 
scored for normal (lamellar) or ballooned/swollen cristae (disorganized) (n=3; two-sided Fisher’s exact 
test). (G) NR treatment reduces mtROS production in GBA KO neurons. GBA KO iPSC-derived neurons 
were treated with NR and mtROS levels were determined with MitoSOX Red using FACS. Data are 
normalized to the corresponding untreated control and represented as mean + SEM (n=5; two-tailed t-
test). (H) Mitochondrial respiration in NR-treated GBA-PD iPSC-neurons. Values for basal OCR, ATP-
linked OCR, and maximal OCR, are shown. Data are represented as mean + SD (n=8; two-tailed t-test). 
(I) Mitochondrial respiration in NR-treated GBA KO iPSC-neurons. Values for basal OCR, ATP-linked 
OCR, and maximal OCR are shown. Data are represented as mean + SD (n=8; two-tailed t-test). (J) GBA-
PD neurons were treated with NR and levels of BiP were assessed by Western blot.  	

Figure S7, related to Figure 6.  
NAD+ boosting treatments in GBA-PD iPSC-neurons. 
(A) Control iPSC-derived neurons were treated with PJ34 and NAD+ levels were measured using a NAD+ 
cycling assay. Data are normalized to untreated and expressed as mean + SEM (n=5; two-tailed t-test).  
(B) Representative TEM images showing GBA-PD iPSC-neurons with or without PJ34 treatment (scale 
bar 500 nm). (C) Quantification of mitochondrial cristae morphology in PJ34 treated and untreated GBA-
PD iPSC-neurons (n=3; two-sided Fisher’s exact test). (D) mtROS in GBA-PD (N370S, L444P) iPSC-
neurons after PJ34 treatment. Data are normalized to the corresponding untreated control and 
represented as mean + SEM (n=3; two-tailed t-test). (E) Mitochondrial respiration in PJ34-treated GBA-PD 
(N370S, L444P) iPSC-neurons. Values for basal OCR, ATP-linked OCR, and maximal OCR, are shown. 
Data are represented as mean + SD (n=5-7; two-tailed t-test). (F) GBA-PD iPSC-neurons were treated 
with NR (+) or vehicle (-) and Western blot analysis for LC3 was performed in iPSC-neurons, untreated (−) 
or treated (+) with 200 µM leupeptin (LP) and 20 mM NH4Cl for 4 hrs. A representative Western blot is 
shown. (G) Quantification of levels of LC3-II (left) and LC3 flux (right). Intensities of Western blot bands 
were normalized to β-Actin. LC3 flux data are normalized to untreated. Data are represented as mean + 
SEM (n=5; two-tailed t-test). (H) GBA KO iPSC-neurons were treated with NR or vehicle and Western blot 
analysis for LC3 was performed in iPSC-neurons, untreated (−) or treated (+) with 200 µM leupeptin (LP) 
and 20 mM NH4Cl for 4 hrs. A representative Western blot is shown. (I) Quantification of levels of LC3-II 
(left) and LC3-II flux (right). Intensities of Western blot bands were normalized to β-Actin. LC3 flux data are 
normalized to untreated. Data are represented as mean + SEM (n=5; two-tailed t-test). (J) LC/MS-based 
targeted metabolomics in iPSC-derived neurons treated with NR. Control and GBA-PD (N370S) iPSC-
neurons were treated with 0.5 mM NR for 24 hours and LC/MS-based targeted NAD+ metabolomics was 
performed. Data are normalized on protein concentration and represented as mean ± SD (n=7 
independent differentiations; two-tailed t-test treated vs untreated). 
				
Table S1, related to Figure 1-6 and Figure S1-S7.  
List of GBA-PD iPSC lines used in the study. 
 
 
 
 
 
 
 
 
 
 
        HC, healthy control; PD, Parkinson’s disease; GC, gene corrected. 	
iPSC clone ID Diagnosis Genotype Genome editing 
C1.1 HC wt/wt  
C1.2 HC wt/wt  
C2 HC wt/wt  
PD1 PD RecNcil/wt  
PD1 GC PD wt/wt Gene corrected line 
PD2 PD L444P/wt  
PD2 GC PD wt/wt Gene corrected line 
PD2-1 PD L444P/wt  
PD3 PD N370S/wt  
PD3 GC PD wt/wt Gene corrected line 
PD4 PD N370S/wt  
Table S2, related to Figure S3. 
List of GBA knockout human iPSC lines generated and used in the study. 
 
 
Parental iPSC line Parental GBA 
genotype 
Derived iPSC clones Derived GBA 
genotype 
C1.2 wt/wt GBA KO # 2 and #7 -/- 
C2 wt/wt GBA KO  #18 and #20 -/- 
PD3 N370S/wt GBA KO #4 and #16 -/- 
 
 
 
GBA knockout iPSC lines generated and used in the study. Table showing the list of GBA knockout 
iPSC lines generated using CRISPR-Cas9. HC, healthy control; PD, Parkinson's disease. 
 	
INVENTORY OF SUPPLEMENTAL INFORMATION  
Supplementary Experimental Procedures  
Detailed description of the experimental procedures and source of materials.  
Figure S1 
Supporting data for Figure 1.  
Figure S2  
Supporting data for Figure 2.  
Figure S3  
Supporting data for Figure 3 and Figure 4. 
Figure S4  
Supporting data for Figure 5.  
Figure S5  
Supporting data for Figure 5.  
Figure S6  
Supporting data for Figure 5.  
Figure S7  
Supporting data for Figure 6.  
Table S1 
List of cell lines used in the study.  
Table S2 
List of GBA knockout human iPSC lines generated and used in the study. 
 
 	
